LONDON, Feb. 25, 2016 /PRNewswire/ -- Dermatophytic onychomycosis is a fungal nail infection caused by dermatophytes. Dermatophytic onychomycosis is also known as tinea unguium. It is called the dermatophytic invasion of the nail plate. It is the most common nail infection and constitutes more than half of all nail disease cases. This condition mostly affects toenails. The overall prevalence rate of dermatophytic onychomycosis is around 10% in the general population. The disease can lead to severe pain and can impede work and social activities.
This report covers the global dermatophytic onychomycosis therapeutics market performance in terms of revenue contribution. The report includes key trends, drivers, restraints, and opportunities influencing the growth of the global dermatophytic onychomycosis therapeutics market. Impact analysis of key growth drivers and restraints, based on the weighted average model, are included to better equip clients with crystal clear decision-making insights.
The global dermatophytic onychomycosis therapeutics market is mainly driven by factors such as increasing the prevalence of dermatophytic onychomycosis, rising aging population, increasing consumer inclination towards maintaining aesthetic appearance of nails, and increasing per capita healthcare expenditure. Potential side effects of therapeutic products, availability of alternative treatments, and lack of awareness in emerging regions such as APEJ and MEA are expected to hinder the growth of the dermatophytic onychomycosis therapeutics market.
On the basis of products, dermatophytic onychomycosis therapeutics market is segmented into tablet and nail paint. Both the segments, tablet and nail paint are further sub-segmented into prescription and over-the-counter products. By distribution channel, dermatophytic onychomycosis therapeutics market is segmented into hospitals, clinics, independent pharmacies, mail order pharmacies, and drug stores.
By product, revenue from the tablet segment is projected to rise at the highest CAGR of 5.2% during the forecast period. The nail paint segment is expected to dominate the market, accounting for a maximum share of the overall market by 2021. The nail paint segment revenue is projected to rise at a CAGR of 8.3% during the forecast period (2015–2021).
By treatment, the topical segment is estimated to dominate the dermatophytic onychomycosis therapeutics market, accounting for a maximum share of the overall market by 2015 end. Revenue from the topical segment is projected to increase at a CAGR of 8.3% during the forecast period.
In terms of value, North America dominated the market with over 43% market share in 2014, followed by Europe. In Asia Pacific, this market is projected to expand at the highest CAGR of 5.1% during the forecast period.
Key players of the global dermatophytic onychomycosis therapeutics market are Valeant Pharmaceuticals International Inc., Galderma S.A., Novartis AG, Pfizer Inc., Moberg Pharma AB, Johnson & Johnson Services, Inc., and Anacor Pharmaceuticals, Inc. Leading players operating in the market collaborate with healthcare solutions and services providers in order to advance operational efficiencies and provide improved patient care.
The dermatophytic onychomycosis therapeutics market is segmented as follows:
By Distribution Channels:
Mail Order Pharmacies
Rest of Europe
Australia & New Zealand
Rest of Asia Pacific
Rest of Latin America
Rest of MEA
Key features included in this report:
Drivers and restraints of the dermatophytic onychomycosis therapeutics market
Latest product innovations and key developments in the market
Analysis of business strategies of the top players
Dermatophytic onychomycosis therapeutics market estimates and forecasts
Download the full report: https://www.reportbuyer.com/product/3658142/
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
For more information:
Research Advisor at Reportbuyer.com
Tel: +44 208 816 85 48